MeiraGTx Reports First Quarter 2026 Financial and Operational Results
MeiraGTx announced its financial and operational results for the first quarter ended March 31, 2026, highlighting the reacquisition of full rights to botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa (XLRP) and the FDA Breakthrough Therapy Designation for AAV2-hAQP1. The company strengthened its balance sheet with a $100 million financing and reported a net loss of $46.3 million for the quarter.
Biogen advances Alzheimer’s drug on suggestion of benefit
Biogen announced it will continue developing its experimental Alzheimer’s drug, diranersen, despite the mid-stage study not meeting its primary goal. The drug targets tau protein tangles in brain cells, and while the study showed promising signs of benefit in slowing disease progression, it raised questions about the consistency of cognitive benefits and side effects. Biogen plans to advance diranersen into a late-stage trial and also mentioned the possibility of combining it with treatments targeting amyloid protein.
How Investors Are Reacting To Johnson & Johnson (JNJ) Expanding Its Coronary Lithotripsy Device Portfolio
Johnson & Johnson's Shockwave Medical unit recently launched the Shockwave C2 Aero coronary intravascular lithotripsy catheter, expanding its MedTech portfolio. While this reinforces J&J's innovation in high-value MedTech, investors are advised to also consider other crucial factors impacting the company's investment narrative. These include the success of new drugs offsetting STELARA revenue losses and the containment of talc litigation and tariff costs, along with varying analyst forecasts for its future revenue and earnings.
Regeneron Pharma stock (US75886F1075): Active in competitive CD38 oncology landscape
Regeneron Pharmaceuticals is developing CD38 x CD3 bispecific antibodies for multiple myeloma within a highly competitive field. While existing CD38 treatments generate significant revenue, Regeneron's approach uses T-cell engagement to differentiate its early-stage candidates. The company maintains a strong revenue base from drugs like Eylea and Dupixent, supporting its innovative immuno-oncology pipeline.
Nanobiotix Stock Hits New Record at €45.86
Nanobiotix stock reached a new all-time high of €45.86 on Thursday, May 14, continuing its significant climb. The stock is up 2.81% for the day, nearly 31% for the week, and has seen a 118% rally over three months and a 1,247% gain over one year. This momentum follows the FDA's validation of an amendment to the Phase 3 NANORAY-312 trial protocol.
Kenvue Inc. Common Stock (NY: KVUE
This article provides a compilation of recent news headlines related to Kenvue Inc. Common Stock (NYSE: KVUE), including analyses of its performance, dividend potential, and analyst perspectives. It features articles from various financial news outlets discussing investment strategies, growth comparisons, and market sentiment surrounding Kenvue and related companies. The listed articles span from December 2023 to January 2024, offering diverse viewpoints on the stock's attractiveness to investors.
Johnson & Johnson R&D Chief Just Outlined the Next Chapter at BofA. Here’s What Investors Should Know
Johnson & Johnson's R&D chief, John Reed, outlined key pipeline developments at the Bank of America Global Healthcare Conference, focusing on ICOTYDE's expansion into IBD, promising RYBREVANT data for head and neck cancer, and the durable growth of SPRAVATO. The article highlights how these innovations, particularly the upcoming ASCO 2026 data for RYBREVANT, are critical for J&J's future growth and could significantly impact its stock valuation, which is currently trading at a premium compared to peers. Investors should closely watch for the RYBREVANT data, as it could be a major catalyst for the stock beyond its current street target.
Amgen stock (US0311621009): Biotech leader navigates patent cliffs and pipeline momentum
Amgen Inc. continues to be a prominent biotech company, strategically managing patent expirations with a strong pipeline, particularly in obesity and cardiovascular treatments. The company demonstrates resilience through diversified revenue streams from blockbuster drugs like Enbrel and Prolia, alongside consistent R&D investment. Amgen's leadership in the biotech sector, reliable dividend payments, and focus on innovation make it a key consideration for US investors.
Pulse Biosciences (NASDAQ: PLSE) Q1 2026 results, cash burn and AF strategy
Pulse Biosciences reported a net loss of $18.6 million in Q1 2026 on modest product revenue of $0.4 million from early sales of its Vybrance Percutaneous Electrode System. The company is strategically realigning its focus and capital towards developing nsPFA electrophysiology catheters and cardiac devices for atrial fibrillation, reducing near-term spending on cardiac surgery market development and Vybrance sales. With $68.3 million in cash and an additional $12.9 million raised post-quarter, Pulse Biosciences anticipates funding operations for at least another year.
MeiraGTx Holdings plc 1Q 2026: Revenue $293K, EPS ($0.57) — 10-Q Summary
MeiraGTx Holdings plc reported its first-quarter 2026 results, showing a significant year-over-year revenue decrease to $293K and an adjusted net loss per share of ($0.57). The company continued advancing its pipeline with four late-stage programs, including the pivotal AQUAx2 study, and secured strategic partnerships with Lilly and Hologen. MeiraGTx also reacquired bota-vec from Janssen and maintained in-house GMP manufacturing, pursuing regulatory filings in multiple regions.
UBS Remains a Hold on AMN Healthcare Services (AMN)
UBS analyst A.J. Rice maintained a Hold rating on AMN Healthcare Services (AMN) with a price target of $32.00, while other analysts provided mixed ratings. The company recently reported Q1 revenue of $1.38 billion and a net profit of $62.17 million.
bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF
This page provides recent news headlines related to bioAffinity Technologies, Inc. (Nasdaq: BIAF), mostly focusing on stock movements, top gainers, and losers in various trading sessions. It aggregates news from sources like Chartmill and Benzinga, with some articles highlighting healthcare stocks and specific company performance. The latest stock price for BIAF is also provided, showing a slight increase.
Ionis partner Biogen announces topline results from phase 2 Celia study of diranersen
Ionis Pharmaceuticals' partner Biogen has announced topline results from the Phase 2 Celia study of diranersen. This news is relevant to investors tracking Ionis Pharmaceuticals (IONS), which focuses on developing medicines for serious diseases, including neurologic and cardiovascular conditions. The article also provides recent analyst ratings and financial data for Ionis.
Mental Health Technology Market Is Going to Boom | Talkspace, BetterHelp, Headspace, Calm
Coherent Market Insights has published a new study titled "Mental Health Technology Market 2026," which provides a detailed evaluation of this market. The report offers high-impact insights into regional and global market growth projections from 2026 to 2033, including market dynamics, value chain analysis, competitive landscape, and market segments. It aims to equip business leaders, investors, and industry participants with strategic tools for identifying growth avenues and optimizing market entry strategies.
The Cooper Companies stock (US2166481027): Drops 0.80% to $59.47
The Cooper Companies stock (COO) dropped 0.80% to $59.47 on May 13, 2026, marking a 27.4% year-to-date decline. Despite the recent dip, the company, specializing in vision care and surgical devices, maintains strong fundamentals and net margins, outperforming some competitors in the healthcare sector. Investors are watching its performance in the growing US healthcare market.
Summit Wealth Group LLC Co. Sells 5,308 Shares of Johnson & Johnson $JNJ
Summit Wealth Group LLC Co. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 56.9% in the fourth quarter, selling 5,308 shares and leaving it with holdings worth approximately $832,000. Despite this institutional selling and recent insider sales by two EVPs totaling over $7 million, Johnson & Johnson has experienced positive analyst momentum, including upgrades and increased price targets, a quarterly earnings beat, and a raised dividend to $1.34 per share. Many other institutional investors, including Vanguard Group and Capital International Investors, significantly increased their positions in JNJ during the same period.
Swiss Life Asset Management Ltd Acquires 69,887 Shares of Kenvue Inc. $KVUE
Swiss Life Asset Management Ltd increased its stake in Kenvue Inc. (NYSE:KVUE) by 19.1% in the fourth quarter, acquiring an additional 69,887 shares to bring its total holding to 435,899 shares valued at approximately $7.5 million. This comes as Kenvue reported strong quarterly results, exceeding EPS estimates with $0.32 and achieving $3.91 billion in revenue. Despite a consensus "Hold" rating from Wall Street analysts with an average price target of $19.33, the company offers a quarterly dividend yielding about 4.8%.
Stryker Corp stock (US8636671013): Medical technology leader with strong US market presence
Stryker Corp is highlighted as a leading medical technology company, innovating in orthopedics, medsurg, and neurotechnology. The article emphasizes its strong market presence in the US, with a significant revenue base from US hospitals. Stryker's robust financial performance in Q1 2026, driven by its diversified product portfolio and strategic acquisitions, positions it well within the growing global medical devices market.
Haleon plc stock (GB00BMX86B70): Consumer health giant focuses on growth amid market shifts
Haleon plc, a leading consumer health company, prioritizes organic growth and margin expansion, with strong performance in its core brands like Sensodyne and Panadol. The company reported 3.9% organic sales growth in 2025 and targets mid-single-digit growth through 2028, driven by innovation, strategic market focus, and a robust US presence. Despite challenges like currency fluctuations, Haleon's defensive stock characteristics and dividend yield make it an appealing option for US investors tracking the expanding consumer health market.
Johnson & Johnson Stock Shares $85 Bil Success With Investors
Johnson & Johnson (JNJ) has returned $85 billion to shareholders through dividends and buybacks over the past five years, ranking 13th historically for capital returned. This strong shareholder return program signals management's confidence in the company's financial health and ability to generate sustainable cash flows. While high capital returns are attractive, the article also notes that they can sometimes indicate lower growth prospects compared to companies like Meta or Microsoft, which reinvest more for faster growth.
Surgical Robotics Market to Reach USD 16.89 Billion by 2033 as
The global surgical robotics market, valued at US$ 6.60 billion in 2025, is projected to hit US$ 16.89 billion by 2033, growing at an 11.3% CAGR. This growth is fueled by increasing demand for minimally invasive surgeries, technological advancements, and the rising prevalence of chronic diseases. North America currently leads the market with a 40% share, while Asia-Pacific is rapidly emerging as a fast-growing region.
How Investors May Respond To 3M (MMM) Joining AI Data Center Optical Connectivity Standards Initiative
3M Company has joined a multi-source agreement to establish open standards for expanded beam optical connectivity in AI data centers, aiming to align its expertise with the growing demand for high-density optical interconnects. While this move supports 3M's innovation narrative, the article notes that near-term investment considerations are still heavily influenced by PFAS litigation and broader market demand. Investors are advised to consider this AI initiative within the broader context of 3M's financial forecasts and existing challenges.
[144] ENvue Medical, Inc. SEC Filing
This article reports on an SEC Form 144 filing by ENvue Medical, Inc. (FEED). The filing indicates a neutral impact and sentiment. The Form 144 details a proposed sale of 30,000 shares of common stock, valued at $35,100, on May 13, 2026, through Robinhood Financial LLC on NASDAQ.
Johnson & Johnson (NYSE:JNJ) Shares Up 2.8% on Analyst Upgrade
Shares of Johnson & Johnson (NYSE:JNJ) rose 2.8% after Johnson Rice upgraded the stock from "hold" to "outperform." This upgrade, alongside positive pipeline data, growth in oncology and immunology, and new product launches, has contributed to a consensus "Moderate Buy" rating and an average target price of $253.04 among analysts. The company also announced an increased quarterly dividend of $1.34 per share.
Becton Dickinson stock (US0718131099): Medical technology leader with global reach
Becton Dickinson (BD), a global medical technology company, is a key player in medical devices and diagnostics, providing products like syringes and diagnostic systems. The company's business model is built around three segments: BD Medical, BD Life Sciences, and BD Interventional, generating steady revenue primarily from consumables. BD offers US investors exposure to defensive healthcare growth, with a strong dividend history and market leadership, though potential investors should consider regulatory risks and high debt from past mergers.
BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration
Bristol Myers Squibb (BMS) and Hengrui Pharma have formed a global strategic collaboration to co-develop 13 early-stage programs in oncology, hematology, and immunology. The agreements could generate over $15.2 billion for Hengrui, with BMS providing an upfront payment of $600 million and additional payments totaling $950 million over two years. This partnership aims to combine the strengths of both companies in drug discovery, clinical development, and commercialization, especially as BMS seeks to offset losses from upcoming patent expirations.
Stereotaxis, Inc. 1Q 2026: Revenue $6.29M, EPS $(0.06) — 10-Q Summary
Stereotaxis, Inc. (STXS) reported first-quarter 2026 results with a revenue of $6.29 million, a decrease of 15.8% from the previous year, and a net loss of $(6.17) million, resulting in a diluted loss per share of $(0.06). The revenue decline was attributed to lower system sales and a transition to proprietary catheters. Despite this, the company saw continued regulatory and product momentum and announced the acquisition of Robocath to expand its robotic interventional portfolio.
J&J launches Shockwave Medical’s next-generation coronary IVL catheter
Johnson & Johnson has launched its new Shockwave C2 Aero Coronary IVL Catheter in the U.S. and Japan, with plans for wider global availability. This fifth-generation device from Shockwave Medical, a J&J MedTech company, incorporates physician feedback to improve deliverability and repositioning for treating calcified coronary artery disease. The launch aims to redefine standards in coronary IVL, a field that is becoming increasingly competitive with other major medtech companies.
Johnson & Johnson stock upgraded at Leerink (JNJ:NYSE)
Leerink Partners upgraded Johnson & Johnson (JNJ) stock to Outperform from Market Perform. The upgrade is based on the pharma giant's growth prospects, particularly due to its newly approved products, Icotyde and Inlexzo. Shares of JNJ have seen gains for the third consecutive session following this news.
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says
An appeals court has ruled that Viatris Inc.'s generic version of Johnson & Johnson unit Actelion Pharmaceuticals Ltd.'s hypertension drug Veletri does not infringe on two of J&J's patents. The court affirmed that Viatris's drug falls below the specific pH range mentioned in the patents, using evidence that pH measurement should be taken at standard temperature. This decision supports the US District Court for the Northern District of West Virginia's initial finding.
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says
Viatris Inc. has successfully argued in an appeals court that its generic version of Johnson & Johnson's hypertension drug Veletri does not infringe on two of J&J's patents. The US Court of Appeals for the Federal Circuit ruled that Viatris's drug falls outside the specified pH range in J&J's patents, upholding a previous decision by the US District Court for the Northern District of West Virginia. This decision allows Viatris to market its generic hypertension drug without patent infringement claims from J&J.
J&J launches improved Shockwave catheter
Johnson & Johnson has launched its new Shockwave C2 Aero catheter, an improved fifth-generation device designed to better treat complex calcified lesions in arteries. The catheter offers enhanced flexibility and easier repositioning, expanding its utility for physicians. This launch reinforces J&J's leading position in the intravascular lithotripsy (IVL) market, a key growth driver, following its 2024 acquisition of Shockwave Medical.
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
FDA Commissioner Marty Makary has resigned following reports of his ouster, leading to an acting commissioner and temporary directors for key review divisions. Sanofi is facing issues with the FDA's new Commissioner’s National Priority Review program for its diabetes prevention drug Tzield. Meanwhile, biopharma CEOs' salaries have increased, and BioSpace is releasing its annual compensation report for 2025.
Abbott Laboratories stock (US0028241000): Q4 earnings call set for Jan. 22
Abbott Laboratories is scheduled to release its Q4 2025 earnings on January 22, 2026, ahead of market open, followed by a conference call. The company, a diversified healthcare leader in diagnostics, medical devices, nutritional products, and pharmaceuticals, recently saw its stock hit a 52-week low due to legal challenges related to infant formula. Investors will be closely watching the earnings call for insights into financial performance and future outlook.
Legend Biotech Corporation (NASDAQ:LEGN) Q1 2026 Earnings Call Transcript
Legend Biotech (NASDAQ:LEGN) reported strong Q1 2026 results, with CARVYKTI net trade sales reaching $597 million, a 52% year-over-year increase, driven by early-line adoption and global expansion. The company is advancing its pipeline, including pivotal Phase III studies for CARVYKTI in frontline multiple myeloma and progress in its In Vivo CAR-T programs for oncology and autoimmune diseases, with initial data from its Non-Hodgkin’s Lymphoma program expected mid-year. Despite higher COGS due to manufacturing expansion, Legend Biotech remains on track for company-wide profitability on an adjusted basis in 2026, supported by its strong balance sheet.
Kenvue stock (US49177J1025): General Counsel sells $679K in shares
Kenvue's General Counsel, Matthew Orlando, sold 38,491 shares of the company's common stock on May 8, 2026, for approximately $679,690, resulting in zero direct ownership. This insider sale occurred after Kenvue reported positive Q1 2026 results, with sales reaching $3.909 billion and net income of $474 million. Kenvue, spun off from Johnson & Johnson, operates in the consumer health sector with brands like Tylenol and Neutrogena, maintaining a strong position in the resilient US market.
Stereotaxis, Inc. (AMEX:STXS) Q1 2026 Earnings Call Transcript
Stereotaxis Inc. (AMEX:STXS) announced their Q1 2026 earnings, reporting an EPS beat at $-0.03 versus an expectation of $-0.04. CEO David Leo Fischel highlighted the company's "amazing start" to the year, driven by new foundational products and regulatory approvals in the US and Europe, despite current quarterly numbers not yet reflecting this progress. The company is transitioning from its legacy business, including its dependency on Johnson & Johnson, towards a new ecosystem with proprietary therapeutic catheters like MAGIC, and anticipates double-digit revenue growth to surpass $40 million for the year.
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion Therapeutics announced the initiation of GMP clinical batch manufacturing for SIL204, its siRNA therapy for KRAS-driven pancreatic cancer, in collaboration with Catalent. This manufacturing milestone, coupled with approval from Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee for the planned Phase 2/3 trial, brings the company closer to first patient dosing. The trial will evaluate SIL204 in combination with standard chemotherapy, utilizing a dual-route administration strategy to target both primary tumors and metastatic disease.
BranchLab Raises $26M Series A Led by McKesson Ventures to Bring AI to Pharma Commercialization
BranchLab, an AI platform for pharmaceutical commercialization, has successfully raised $26 million in Series A funding, led by McKesson Ventures with participation from Sanofi Ventures, FCA Venture Partners, and AIX Ventures, bringing their total funding to $35 million. The company aims to transform pharma commercialization by replacing fragmented, manual workflows with a unified, privacy-first AI platform that increases marketing efficacy by nearly 70%. BranchLab's technology uses a novel transformer-based architecture to provide real-time insights and activation while adhering to strict privacy standards, allowing pharma teams to connect patients and healthcare professionals with therapies more efficiently and responsibly.
World Investment Advisors Raises Position in Johnson & Johnson $JNJ
World Investment Advisors significantly increased its stake in Johnson & Johnson by 19.6% in the fourth quarter, bringing its total holding to 161,343 shares valued at approximately $33.4 million. This move follows J&J's strong Q1 earnings, where the company beat analyst expectations with an EPS of $2.70 and revenue of $24.06 billion, subsequently raising its full-year FY2026 guidance. Analysts maintain a "Moderate Buy" consensus rating for Johnson & Johnson, with an average price target of $252.48, reinforced by an increased quarterly dividend of $1.34 per share.
Grifols S.A. stock (ES0171996087): Leading player in plasma-derived medicines
Grifols S.A. is a global leader in plasma-derived medicines and biologics, with a strong presence in the US market through its products and extensive plasma collection network. The company's vertically integrated model, from plasma donation to finished products, helps ensure supply control in a market prone to shortages, appealing to investors interested in defensive healthcare plays. Grifols differentiates itself from competitors through its extensive US plasma network and its scale in plasma fractionation.
SSR Mining Stock 5-Day Winning Spree: Stock Climbs 27%
SSR Mining (SSRM) experienced a significant 5-day winning streak, with its stock climbing 27% and its market cap increasing by $1.5 billion to reach $7.3 billion. Despite past drops, the company shows strong operating performance and a moderate valuation, making it an attractive investment according to Trefis. The article also provides a comparison of SSRM's returns against the S&P 500 and highlights its key financial metrics over the last two fiscal years and quarters.
Haleon plc stock (GB00BMX86B70): Consumer health giant navigates post-spin-off growth
Haleon plc, the consumer health spin-off from GSK, focuses on power brands like Sensodyne and Panadol, maintaining a strong global presence in oral care, pain relief, and digestive health. US investors are interested in Haleon for its exposure to stable consumer staples and its strong North American market footprint, providing defensive qualities amid economic shifts. The company differentiates itself through science-backed brands and sustainable initiatives within a growing consumer health sector.
Englebert Financial Advisers LLC Acquires Shares of 5,278 Johnson & Johnson $JNJ
Englebert Financial Advisers LLC has acquired 5,278 shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, valued at approximately $1.09 million, making it the 16th largest holding in their portfolio. This comes as J&J reported strong Q4 earnings, surpassing analyst expectations for both EPS and revenue, and raising its full-year guidance. The company also increased its quarterly dividend, reflecting a positive outlook from both the company and analysts, who maintain a "Moderate Buy" consensus rating.
Blackhawk Capital Partners LLC Reduces Stock Position in Johnson & Johnson $JNJ
Blackhawk Capital Partners LLC significantly reduced its stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, selling 5,920 shares to hold 1,344 shares valued at $278,000. Despite this reduction, Johnson & Johnson reported strong Q1 earnings, with EPS of $2.70 and revenue of $24.06 billion, and raised its quarterly dividend. The company also reaffirmed its FY 2026 EPS guidance, maintaining a "Moderate Buy" consensus rating from analysts with an average price target of $252.48.
Sinovac Foundation donates 3.83 lakh doses of polio vaccine to Bangladesh
The Sinovac Foundation, a subsidiary of China's Sinovac Biotech Limited, has donated 3.83 lakh doses of polio vaccine to Bangladesh. This donation aims to bolster the Bangladesh government's Expanded Programme on Immunization (EPI) and support global polio eradication efforts. Health Minister Sardar Md. Sakhawat Husain expressed gratitude to China, highlighting the challenge of managing various diseases despite successful measles vaccination campaigns.
BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
Legend Biotech Corp. reported a significant 56% year-on-year revenue increase to $305.1 million in the first quarter, driven by robust sales of its cancer treatment, Carvykti. The company, in partnership with Johnson & Johnson’s Janssen unit, saw its net loss nearly halve to $54.3 million. Following these positive results, Legend Biotech's New York-listed stock rose 10.5% on Tuesday, bringing its year-to-date gain to 31%.
White House Reportedly Preparing To Oust FDA Commissioner Marty Makary
The White House is reportedly considering replacing current FDA Commissioner Marty Makary, with FDA Deputy Commissioner Kyle Diamantas among potential interim candidates. Makary's potential ousting follows internal friction over vaping policy and drug approval decisions, and his rise to prominence during the COVID-19 pandemic as a critic of public health establishments. President Trump, however, has stated he knows "nothing about" the reports of Makary's removal.
Meet 3 leaders breaking new ground for women in healthcare
This article highlights three Johnson & Johnson leaders—Kimberly Lounds Foster, Soumya D. Chakravarty, and Carmen Canovas Vidal—who are making significant contributions to healthcare through their STEM expertise. They discuss their inspirations for entering the healthcare field, the specifics of their roles in developing and delivering therapies and medical devices, and the broader impact of STEM careers on patient lives. The leaders emphasize the rewarding nature of their work and offer advice for aspiring professionals in STEM.
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
Legend Biotech reported strong first-quarter 2026 results, with CARVYKTI® net trade sales increasing 62% year-over-year to approximately $597 million. The company expanded CARVYKTI® availability to 18 global markets and achieved a 99% manufacturing success rate. Despite an operating loss of $49.8 million, the net loss improved significantly to $54.3 million from $101.0 million in the prior year, driven by higher gross profit from CARVYKTI®.
